LanthaScreen® TR-FRET Progesterone Receptor Coactivator Assay Kit

Catalog number: A15903

 Related applications: Target & Lead Identification & Validation

Error loading your content!

  Catalog number
Select a plan
Unit size
List price ({{currency}}) Your price ({{currency}}) Availability Qty
{{product.sku}} {{product.sku}}
also known as {{product.formattedSku}} 
{{subscriptionDetails.selectedRatePlan.billingPeriod}} {{subscriptionDetails.selectedRatePlan.billingPeriod}} {{product.availability.message}}
Pro add-ons

Your on-site stock

›› {{supplyCenter.scName}}({{scProduct.stockOnHand}} In stock)
›› {{supplyCenter.scName}}(Out of stock)
›› {{supplyCenter.scName}}
This item is not currently available on-site. Depending on your Supply Center settings you may be able to add the item to cart above else use the Order Non-Stocked Items' tab on the Supply Center home page.
Back to top

Description

The LanthaScreen® TR-FRET Progesterone Receptor Coactivator Assay Kit provides a sensitive and robust method for high-throughput screening of potential progesterone receptor (PR) ligands as agonists or antagonists of ligand-dependent coactivator recruitment. The kit uses a PR ligand--binding domain (PR-LBD) tagged with glutathione-S-transferase (GST) (also available separately), a terbium (Tb)-labeled anti-GST antibody, and a fluorescein-labeled coactivator peptide in a homogenous mix-and-read assay format.

Agonist Mode
When using the LanthaScreen TR-FRET Progesterone Receptor Coactivator Assay in agonist mode (to identify agonist compounds), PR-LBD is added to ligand test compounds, followed by the addition of a mixture of fluorescein-labeled coactivator peptide and Tb-labeled anti-GST antibody. After an incubation period at room temperature, the TR-FRET ratio of 520/495 nm is calculated and can be used to determine the EC50 from a dose response curve of the compound. Based on the biology of the PR-coactivator peptide interaction, this ligand EC50 is a composite value representing the amount of ligand required to bind to receptor, effect a conformational change, and recruit coactivator peptide (see figure).

Antagonist Mode
When using the LanthaScreen™ TR-FRET Progesterone Receptor Coactivator Assay in antagonist mode (to identify antagonist compounds), PR-LBD is added to ligand test compounds followed by addition of a mixture of agonist, fluorescein-labeled coactivator peptide, and terbium-labeled anti-GST antibody (see figure). The concentration of agonist used in this mode is the EC80 concentration as determined by first running the assay in agonist mode.
For Research Use Only. Not for use in diagnostic procedures.

Specifications

Product Size: 800 x 20 µL assays
Validated Application: Co-Factor Interaction Assay, Nuclear Receptor Assay

Contents & storage

1 tube PR Ligand Binding Domain Recombinant Protein (store at -68 to -85°C)
1 tube of Peptide (store at -5 to -30°C)
2 bottles TR-FRET Buffer (store at -5 to -30°C)
1 tube Tb-Anti-GST Ab (store at -5 to -30°C)
1 tube of DTT (store at -5 to -30°C)

Documents

Manuals & protocols

Recommended products